Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase NA 1

Status

Recruiting 9Completed 7Unknown 3Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 5Observational 2

Sponsor

Cancer Type

Thoracic 7

Conditions

Breast Neoplasms 6384Neoplasms 5356Prostatic Neoplasms 2964Carcinoma, Non-Small-Cell Lung 2704Colorectal Neoplasms 2674Lung Neoplasms 2262Multiple Myeloma 1656Lymphoma 1598Neoplasm Metastasis 1550Leukemia, Myeloid, Acute 1537Melanoma 1484Pancreatic Neoplasms 1470Ovarian Neoplasms 1420Leukemia 1387Head and Neck Neoplasms 1283Precursor Cell Lymphoblastic Leukemia-Lymphoma 1279Lymphoma, Non-Hodgkin 1226Colonic Neoplasms 1157Carcinoma, Hepatocellular 1141Stomach Neoplasms 1126Leukemia, Lymphocytic, Chronic, B-Cell 1089Brain Neoplasms 1048Rectal Neoplasms 979Lymphoma, Follicular 978Recurrence 971Uterine Cervical Neoplasms 923Glioblastoma 916Carcinoma, Renal Cell 881Lymphoma, Large B-Cell, Diffuse 851Hodgkin Disease 775

Interventions

toripalimab 2sintilimab 2Surveys and Questionnaires 1Pemetrexed 1Paclitaxel 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Completed × Advanced Lung Cancer × Clear all
NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

NCT05000684 2025-02-20

Study of JS004 Combined With Toripalimab for Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
67 enrolled
Thoracic

Advanced Lung Cancer

NCT04672356 2023-06-22

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
19 enrolled
Thoracic

Advanced Lung Cancer

NCT04672369 2023-06-22

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
42 enrolled
Thoracic

Advanced Lung Cancer

NCT04069494 2020-07-17

Descriptors and Predictors of Burden and Information Needs

Chulabhorn Cancer Center

Completed
112 enrolled
Thoracic

Advanced Lung Cancer

NCT04352335 2020-07-02

Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator

Chung Shan Medical University

Completed
53 enrolled
Thoracic

Advanced Lung Cancer

NCT02801734 2018-03-29

EQUIP

National Cancer Centre, Singapore

Phase NA Completed
69 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡